Summary
BeOne Medicines Ltd. (ONC) announced a significant regulatory milestone with the European Commission granting marketing authorization for BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed/refractory marginal zone lymphoma (MZL). This approval, effective across all 27 EU member states, Iceland, and Norway, follows at least one prior anti-CD20-based therapy. This development is a key step in expanding BRUKINSA's market reach and potential revenue streams in a major global market.
Key Highlights
- 1European Commission grants marketing authorization for BRUKINSA® (zanubrutinib).
- 2Indication is for adult patients with relapsed/refractory marginal zone lymphoma (MZL).
- 3Patient population requires at least one prior anti-CD20-based therapy.
- 4Approval covers all 27 EU member states, plus Iceland and Norway.
- 5This represents a significant geographic expansion for BRUKINSA®.
- 6The announcement was made via a press release filed as an exhibit to the 8-K.